SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-16-039160
Filing Date
2016-09-27
Accepted
2016-09-27 16:47:39
Documents
7
Period of Report
2016-11-10
Effectiveness Date
2016-09-27

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A bota20160927_def14a.htm DEF 14A 910638
2 a4.jpg GRAPHIC 128758
3 a3.jpg GRAPHIC 132147
4 a2.jpg GRAPHIC 184404
5 a1.jpg GRAPHIC 91420
6 bota20160927_def14aimg002.gif GRAPHIC 1962
7 bota20160927_def14aimg001.gif GRAPHIC 1921
  Complete submission text file 0001437749-16-039160.txt   1657047
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-35285 | Film No.: 161904921
SIC: 2836 Biological Products, (No Diagnostic Substances)